Implanterbar defibrillator - med fokus på primärprofylax. Förutsätter utförlig patientinformation om risker och vinster
Engelsk titel: Implantable defibrillator - with focus on primary prevention. Detailed patient information about risks and benefits is required
Läs online
Författare:
Jensen SM
;
Kesek M
Email: steen.jensen@medicin.umu.se
Språk: Swe
Antal referenser: 29
Dokumenttyp:
Översikt
UI-nummer: 09121027
Sammanfattning
The absolute risk reduction for death is 8% in primary prophylactic and secondary prophylactic ICD therapy. The impact of the randomised ICD studies has short follow up and the risk reduction is likely overstated due to differences in treatment with beta-blockers and anti-arrhythmic drugs between the study groups. During an ICD's lifetime 25 % of the patients experience inappropriate shock and 25 % are re-operated one or more times. Before decision of primary prophylactic ICD therapy the patient and the physician must weigh the size of risk reduction against the risk of side effects. The impact of primary prophylactic ICD therapy must be systematically monitored and evaluated in register studies.